Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol - Usman, Z; Mijočević, H; Karimzadeh, H; Al-Mahtab, M; Bazinet, M; Frishman, D; Vaillant, A; Roggendorf, M (Zeitschrift für Gastroenterologie, 2019)